MX2020001832A - Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. - Google Patents

Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.

Info

Publication number
MX2020001832A
MX2020001832A MX2020001832A MX2020001832A MX2020001832A MX 2020001832 A MX2020001832 A MX 2020001832A MX 2020001832 A MX2020001832 A MX 2020001832A MX 2020001832 A MX2020001832 A MX 2020001832A MX 2020001832 A MX2020001832 A MX 2020001832A
Authority
MX
Mexico
Prior art keywords
sup
pyruvate kinase
blood disorders
treating blood
kinase activators
Prior art date
Application number
MX2020001832A
Other languages
English (en)
Inventor
Tao Liu
Zhenwei Cai
Dawei Cui
Zhihua Sui
Giovanni Cianchetta
Anil Kumar Padyana
Jingjing Ji
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2020001832A publication Critical patent/MX2020001832A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos que activan la piruvato quinasa, composiciones farmacéuticas y métodos para usarlos. Estos compuestos están representados por la fórmula (I): (ver Fórmula) donde R1, R2, Ra, Rb, Rj, Rk y Q son como se los define en la presente.
MX2020001832A 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. MX2020001832A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number Publication Date
MX2020001832A true MX2020001832A (es) 2020-07-22

Family

ID=63524352

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001832A MX2020001832A (es) 2017-08-15 2018-08-15 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MX2020001833A MX2020001833A (es) 2017-08-15 2018-08-15 Moduladores de piruvato quinasas y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001833A MX2020001833A (es) 2017-08-15 2018-08-15 Moduladores de piruvato quinasas y uso de los mismos.

Country Status (32)

Country Link
US (7) US11364240B2 (es)
EP (4) EP4026838A1 (es)
JP (4) JP7275107B2 (es)
KR (3) KR102642408B1 (es)
CN (3) CN111032046B (es)
AU (3) AU2018316588B2 (es)
BR (2) BR112020003262A2 (es)
CA (2) CA3071993A1 (es)
CL (1) CL2020000375A1 (es)
CO (2) CO2020002961A2 (es)
CR (1) CR20200123A (es)
CY (1) CY1124953T1 (es)
DK (2) DK3668513T3 (es)
EC (1) ECSP20018487A (es)
ES (3) ES2966825T3 (es)
FI (1) FI3668512T3 (es)
HR (2) HRP20230452T1 (es)
HU (2) HUE061910T2 (es)
IL (3) IL272599B (es)
LT (2) LT3668512T (es)
MD (1) MD3668513T2 (es)
MX (2) MX2020001832A (es)
PE (1) PE20200724A1 (es)
PH (1) PH12020500343A1 (es)
PL (2) PL3668513T3 (es)
PT (2) PT3668513T (es)
RS (2) RS64221B1 (es)
SG (2) SG11202001353PA (es)
SI (2) SI3668513T1 (es)
TW (3) TWI796353B (es)
UA (1) UA126292C2 (es)
WO (3) WO2019035863A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014032A (es) 2017-03-20 2019-08-21 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
CN111032046B (zh) 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
JPWO2020262419A1 (es) * 2019-06-26 2020-12-30
AU2021311597A1 (en) * 2020-07-21 2023-02-02 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
CA3231728A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
AU2022390088A1 (en) * 2021-11-16 2024-05-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
KR20020091829A (ko) 1999-07-30 2002-12-06 애보트 게엠베하 운트 콤파니 카게 2-피라졸린-5-온
EP1214296B1 (en) 1999-09-04 2004-03-24 AstraZeneca AB Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2009274027A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010025202A1 (en) * 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
CA3041868C (en) 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
CA2758071C (en) * 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
IN2012DN00471A (es) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
RU2675656C2 (ru) * 2011-05-03 2018-12-21 Аджиос Фармасьютикалз, Инк. Способы применения активаторов пируваткиназы
AU2012250690B2 (en) 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
US8969363B2 (en) * 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EP2917207A1 (en) * 2012-11-08 2015-09-16 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
EP2951181A1 (en) * 2013-01-30 2015-12-09 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
MX365950B (es) * 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TWI789401B (zh) 2017-07-07 2023-01-11 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AR112690A1 (es) 2017-08-15 2019-11-27 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CN111032046B (zh) 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
WO2019035864A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
CN111032045A (zh) 2020-04-17
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
JP2023027276A (ja) 2023-03-01
MX2020001833A (es) 2020-07-22
WO2019035864A8 (en) 2019-03-28
RU2020110573A3 (es) 2021-12-24
WO2019035863A8 (en) 2019-03-28
RS62871B1 (sr) 2022-02-28
IL272599A (en) 2020-03-31
PL3668513T3 (pl) 2022-03-21
CN111032046B (zh) 2023-09-26
UA126292C2 (uk) 2022-09-14
EP3668513B1 (en) 2021-11-10
IL272597A (en) 2020-03-31
SI3668513T1 (sl) 2022-04-29
CR20200123A (es) 2020-06-29
KR20200054200A (ko) 2020-05-19
PL3668512T3 (pl) 2023-06-19
IL272599B (en) 2022-08-01
TWI790271B (zh) 2023-01-21
BR112020003262A2 (pt) 2020-09-01
AU2018316588B2 (en) 2023-02-02
PE20200724A1 (es) 2020-07-21
EP4026838A1 (en) 2022-07-13
AU2018316587A1 (en) 2020-02-20
ECSP20018487A (es) 2020-05-29
WO2019035865A8 (en) 2019-03-28
JP7301040B2 (ja) 2023-06-30
CN117186119A (zh) 2023-12-08
CY1124953T1 (el) 2023-01-05
CO2020002961A2 (es) 2020-04-13
AU2018316587B2 (en) 2023-05-11
JP2023052478A (ja) 2023-04-11
BR112020003254A2 (pt) 2020-10-27
HRP20220039T1 (hr) 2022-04-15
RS64221B1 (sr) 2023-06-30
SG11202001353PA (en) 2020-03-30
EP3668512B1 (en) 2023-02-15
IL272597B (en) 2022-06-01
US20230226055A1 (en) 2023-07-20
IL292530B2 (en) 2023-06-01
JP2020531443A (ja) 2020-11-05
JP7275107B2 (ja) 2023-05-17
IL292530A (en) 2022-06-01
US11872225B2 (en) 2024-01-16
EP3668881B1 (en) 2023-10-04
SG11202001262QA (en) 2020-03-30
US11364240B2 (en) 2022-06-21
CL2020000375A1 (es) 2020-12-11
AU2023202772A1 (en) 2023-05-18
TW202323258A (zh) 2023-06-16
WO2019035865A1 (en) 2019-02-21
MD3668513T2 (ro) 2022-04-30
DK3668512T3 (da) 2023-05-22
HUE057178T2 (hu) 2022-04-28
EP3668513A1 (en) 2020-06-24
US20220233541A1 (en) 2022-07-28
CO2020002959A2 (es) 2020-04-13
AU2018316588A1 (en) 2020-02-20
KR20200054199A (ko) 2020-05-19
HUE061910T2 (hu) 2023-08-28
US11590132B2 (en) 2023-02-28
US11957680B2 (en) 2024-04-16
SI3668512T1 (sl) 2023-06-30
WO2019035863A1 (en) 2019-02-21
RU2020110573A (ru) 2021-09-16
TWI796353B (zh) 2023-03-21
CN111032045B (zh) 2023-08-15
US20210130371A1 (en) 2021-05-06
ES2905100T3 (es) 2022-04-07
KR102642408B1 (ko) 2024-02-28
EP3668881A1 (en) 2020-06-24
JP2020531432A (ja) 2020-11-05
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
US20220395503A1 (en) 2022-12-15
FI3668512T3 (fi) 2023-05-12
ES2944545T3 (es) 2023-06-22
CN111032046A (zh) 2020-04-17
US20210077490A1 (en) 2021-03-18
CA3072455A1 (en) 2019-02-21
US11040036B2 (en) 2021-06-22
US20200206225A1 (en) 2020-07-02
US11464775B2 (en) 2022-10-11
US20200207785A1 (en) 2020-07-02
KR20230127364A (ko) 2023-08-31
TW201920203A (zh) 2019-06-01
AU2023202772B2 (en) 2024-05-16
LT3668513T (lt) 2022-03-25
DK3668513T3 (da) 2022-01-10
PT3668512T (pt) 2023-05-22
PH12020500343A1 (en) 2021-02-08
TW201919631A (zh) 2019-06-01
EP3668512A1 (en) 2020-06-24
LT3668512T (lt) 2023-06-12

Similar Documents

Publication Publication Date Title
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
WO2018039077A8 (en) Therapeutic compounds
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
PH12019500198A1 (en) Compounds and compositions and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
GEP20186893B (en) Pyrazines modulators of gpr6